Aug 15
Opportunity
Participants expect some flexibility and do not want clinical trial participation to significantly impact their normal daily schedule. Sponsors should consider exploring solutions that allow participants to more easily find and select times for appointments, especially with increased flexibility and more diverse procedure locations.
Considerations to Help Action the Opportunity
- Understand the individual needs of each participant and their preferences
- Partner with sites to build flexibility into the clinical trial design by providing timing and location options for visits
- Explore decentralized clinical trial options, such as telemedicine and the use of local clinics and sites
Value and Potential Benefits
- Increases flexibility and ease of scheduling
- Encourages patient engagement and empowers patients
- Reduces the barriers to finding and attending appointments potentially leading to better compliance and retention
Related Blog Posts
Are Pragmatic Trials The Patient Recruitment Solution We’ve Been Looking For?
The age-old problem for clinical research has been the ability to recruit patients. Many clinical research professionals have tried to crack this nut, whether with technology or partnerships or both. Let’s not forget the height of DCTs during the pandemic, which served their purpose but appear to have lost luster in the last few years.…
Solving the Clinical Trial Data Problem
In a new LinkedIn article, Janice Chang, CEO of TransCelerate, and Nicholas Brooke, CEO of The Synergist & PFMD, outline how efforts like the Clinical Trial Data Network, supported by TransCelerate through technical expertise and industry-vetted solutions from our Digital Data Flow initiative, aim to make clinical trial information more structured, connected, and accessible across…
The Clinical Trial Enterprise: Can AI Fix It?
Artificial Intelligence (AI) is reasonably well established in discovery and preclinical research, with success in areas such as target identification and molecular modeling. However, in clinical development, adoption has been fragmented and challenging to embed across the lifecycle. Read the full article by Rob DiCicco from Drug Discovery News here.